Therapeutic Advances in Endocrinology and Metabolism最新文献

{"title":"Multisystem pathology in chronic variable stress: gut-liver-brain axis disruption and the therapeutic promise of magnesium-L-theanine.","authors":"Kazim Sahin, Gozde Erek","doi":"10.1177/20420188261451345","DOIUrl":"10.1177/20420188261451345","url":null,"abstract":"<p><p>Chronic variable stress (CVS) is a well-established translational model that captures the unpredictability, persistence, and cumulative burden of long-term stress exposure. Through repeated application of heterogeneous mild-to-moderate stressors in a non-habituating manner, CVS induces sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis, chronic glucocorticoid excess, oxidative stress, and neuroinflammatory signaling. These processes collectively drive coordinated dysfunction across multiple organ systems. Accumulating evidence now indicates that CVS pathology extends beyond the central nervous system (CNS), engaging the gut-liver-brain axis as a key integrative network linking stress to systemic metabolic and inflammatory outcomes. Stress-induced impairment of intestinal barrier integrity, dysregulation of nutrient transporters, hepatic lipid accumulation, iron dyshomeostasis, and cardiometabolic disturbances synergistically amplify both peripheral and neural vulnerability. Magnesium-L-theanine (MgT), a novel complex combining magnesium with the green tea-derived amino acid L-theanine, has emerged as a promising multi-target intervention against CVS-induced multisystem injury. Preclinical studies demonstrate that MgT preserves epithelial barrier architecture, restores tight junction and mucus-associated proteins, normalizes intestinal nutrient transporter expression, and attenuates hepatic steatosis, oxidative stress, and iron-driven metabolic damage under CVS conditions. These protective effects converge on the reactivation of key metabolic regulators, including nicotinamide adenine dinucleotide (NAD⁺)/sirtuin 1 (SIRT1) and PPARγ signaling pathways, positioning MgT as a modulator of metabolic flexibility and redox resilience. Co-administration with the NAD⁺ precursor nicotinamide riboside further potentiates these responses by reinforcing NAD⁺ availability and downstream metabolic control. In parallel, human studies of magnesium and L-theanine supplementation report anxiolytic, antidepressant, sleep-promoting, and anti-inflammatory benefits, supporting the translational relevance of this combined approach. This review integrates current evidence on CVS-induced multisystem pathology, with a focus on the gut-liver-brain axis, and proposes MgT as a trace-element-based, systems-oriented strategy to mitigate chronic stress-related gastrointestinal, metabolic, and neuropsychiatric complications, while highlighting key mechanistic gaps and translational priorities for clinical advancement.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261451345"},"PeriodicalIF":7.8,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13195228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association and prognostic value of adiposity distribution indices for all-cause mortality in cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide study.","authors":"Nan Tang, Shurun Zuo, Ya'nan Hu, Shizhong Cheng, Xuejin Chen, Haoran Li, Qingdui Zhang, Ji Hao, Chunmei Qi","doi":"10.1177/20420188261449986","DOIUrl":"10.1177/20420188261449986","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic syndrome (CKM) is a major public health challenge. While obesity is a central driver of CKM, body mass index (BMI) fails to adequately reflect body fat distribution and its associated prognostic heterogeneity.</p><p><strong>Objectives: </strong>To evaluate the prognostic value of emerging anthropometric indices reflecting fat distribution in predicting all-cause mortality risk among individuals in the early and intermediate stages of CKM (stages 0-3).</p><p><strong>Design: </strong>A population-based retrospective cohort study utilizing data from the National Health and Nutrition Examination Survey (NHANES) 1999-2006, with mortality linkage follow-up through 2019.</p><p><strong>Methods: </strong>We analyzed 5907 adults with CKM stages 0-3. Eleven adiposity indices were evaluated using four machine learning algorithms (LASSO-Cox, RSF-Boruta, RSF, survival XGBoost) to identify key mortality predictors. Statistical analyses incorporated multivariable Cox proportional hazards regression, restricted cubic splines, false discovery rate (FDR) correction for multiple testing, and a sensitivity analysis across the entire CKM continuum (stages 0-4).</p><p><strong>Results: </strong>Four indices reflecting peripheral-to-central adiposity predominance (TCWR, CWR, AWR, SWR) were consistently identified as key predictors. Higher levels independently correlated with lower all-cause mortality (all FDR-adjusted <i>p</i> < 0.05). TCWR and CWR showed linear inverse trends, whereas AWR and SWR exhibited nonlinear threshold effects. These associations persisted across BMI subgroups and remained robust in the full CKM continuum subanalysis. The combined index model yielded improved discriminative ability (AUC = 0.769) compared to single indices (TCWR AUC = 0.731) and conventional BMI-based models, providing higher net clinical benefit.</p><p><strong>Conclusion: </strong>Peripheral-to-central adiposity indices are strong predictors of mortality in CKM stages 0-3, providing prognostic information beyond BMI and serving as practical tools for early risk stratification. Future studies should evaluate their dynamic changes and validate their applicability across diverse populations.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261449986"},"PeriodicalIF":7.8,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association is not yet an indication: concerns about monitoring claims and residual confounding in outpatient metformin-associated lactate elevation.","authors":"Anxin Wen","doi":"10.1177/20420188261450378","DOIUrl":"10.1177/20420188261450378","url":null,"abstract":"","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261450378"},"PeriodicalIF":7.8,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13187414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The type 2 deiodinase Thr92Ala polymorphism and cognitive aging: current evidence and biological context.","authors":"Yuxian Bing, Yulin Liu, Zufei Zhou, Yuanmeng Li, Yichen Han, Guoning Meng, Yaqiu Jiang","doi":"10.1177/20420188261444838","DOIUrl":"10.1177/20420188261444838","url":null,"abstract":"<p><p>Type 2 iodothyronine deiodinase (DIO2) plays a central role in regulating thyroid hormone (TH) metabolism in the brain by catalyzing the conversion of thyroxine (T4) to the active triiodothyronine (T3), thereby ensuring adequate local TH signaling in neural tissues. Among DIO2 genetic variants, the Thr92Ala (rs225014) polymorphism has been extensively investigated in relation to TH homeostasis and diverse clinical phenotypes. Accumulating evidence suggests a potential association between the Thr92Ala variant and cognitive aging; however, findings across studies remain inconsistent. Proposed mechanisms include altered local TH availability, mitochondrial dysfunction, oxidative stress, and cerebrovascular regulation, although the relative contribution of these pathways has not been fully clarified. Emerging data further indicate that the cognitive effects attributed to the Thr92Ala polymorphism may be context-dependent and influenced by factors such as thyroid functional status, sex, genetic background, and age. In this narrative review, we integrate molecular, physiological, and clinical evidence linking the DIO2 Thr92Ala polymorphism to cognitive aging, with particular emphasis on biological context and sources of heterogeneity that may underlie divergent findings across populations. Rather than providing a quantitative synthesis, we aim to contextualize existing data within the broader regulatory framework of TH signaling to better understand how DIO2-related variation may contribute to brain aging.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261444838"},"PeriodicalIF":7.8,"publicationDate":"2026-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13169097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maternal TPO-Ab status modulates associations between gestational thyroid hormones and neonatal TSH in 10,154 Chinese mother-newborn pairs.","authors":"Huihui Wang, Sijie Xi, Xusheng Chen, Zhaolong Zhan, Xiaosong Yuan, Bin Zhang","doi":"10.1177/20420188261446409","DOIUrl":"10.1177/20420188261446409","url":null,"abstract":"<p><strong>Background: </strong>Evidence on the maternal-fetal thyroid hormone (TH) axis is limited, especially regarding how maternal thyroid peroxidase antibody (TPO-Ab) status affects the link between gestational thyroid function and neonatal thyroid-stimulating hormone (TSH).</p><p><strong>Objectives: </strong>This study explored how maternal TH in late pregnancy influences neonatal TSH and assessed whether TPO-Ab modifies this relationship.</p><p><strong>Design: </strong>This retrospective cohort study was conducted at a tertiary specialized hospital.</p><p><strong>Methods: </strong>A total of 10,154 eligible mother-newborn pairs were analyzed. Maternal TSH, free thyroxine (FT4), free triiodothyronine (FT3), and TPO-Ab were measured before birth; neonatal TSH was measured 3-7 days postbirth. Mothers were classified as TPO-Ab positive (>34 IU/mL) or negative.</p><p><strong>Results: </strong>Maternal TPO-Ab positivity prevalence was 5.5%, while congenital hypothyroidism (CH) screening positivity (TSH ⩾10 mIU/L) occurred in 0.87% of neonates. Among TPO-Ab-negative mothers, maternal TSH positively correlated with elevated neonatal TSH (adjusted β: 0.14, 95% confidence interval (CI): 0.10-0.17, <i>p</i> < 0.001) and CH risk (adjusted odds ratio: 1.21, 95% CI: 1.09-1.33, <i>p</i> < 0.001). A nonlinear dose-response relationship revealed a threshold at 4.85 mIU/L: below this value, neonatal TSH increased sharply with maternal TSH (β: 0.21, 95% CI: 0.16-0.26, <i>p</i> < 0.001). No significant associations existed in TPO-Ab-positive mothers. TPO-Ab status reversed the neonatal TSH-maternal FT3/FT4 ratio relationship: negative correlation in TPO-Ab-negative mothers (β: -1.78, 95% CI: -2.70 to -0.87, <i>p</i> < 0.001) versus positive correlation in TPO-Ab-positive mothers (β: 11.31, 95% CI: 2.03-20.58, <i>p</i> = 0.017).</p><p><strong>Conclusion: </strong>Maternal TSH correlates with neonatal TSH in TPO-Ab-negative pregnancies with a threshold at 4.85 mIU/L. TPO-Ab abolishes this association and reverses the FT3/FT4 ratio-neonatal TSH relationship, establishing TPO-Ab status as a critical modifier of maternal-fetal thyroid interactions. These findings support integrating TPO-Ab screening into prenatal thyroid management to optimize neonatal outcomes. However, the observational design limits causal inference, and further prospective studies are warranted.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261446409"},"PeriodicalIF":7.8,"publicationDate":"2026-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological and interpretative concerns in assessing metabolic syndrome trends following COVID-19 in Jordan.","authors":"Yousef Khader","doi":"10.1177/20420188261444283","DOIUrl":"10.1177/20420188261444283","url":null,"abstract":"","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261444283"},"PeriodicalIF":7.8,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147875836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary.","authors":"Ronette L Kolotkin, Rajitha K, Henrik Brandi, Julie Hviid Hahn-Pedersen","doi":"10.1177/20420188261437874","DOIUrl":"https://doi.org/10.1177/20420188261437874","url":null,"abstract":"<p><p>What is this summary about? Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesity. A study published in 2024 reported on the experiences of people taking semaglutide. People living with obesity who took semaglutide had improvements in their physical, emotional, and social health. Sharing the experiences of people taking weight loss medications may help others make important treatment decisions. What is the purpose of this plain language summary? Semaglutide is an approved medication for weight loss. In a recent study, people who lost weight while taking semaglutide had improved physical, mental, and social health. The goal of this summary is to share the study results in accessible language so that people living with obesity can make informed decisions about whether a medication for weight loss is right for them.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261437874"},"PeriodicalIF":4.6,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13153531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study.","authors":"Víctor Navas-Moreno, Marta Araujo-Castro, María Sara Tapia-Sanchiz, Fernando Sebastián-Valles, Miguel Antonio Sampedro-Núñez, Nuria Sánchez de la Blanca, Rebeca Martínez-Hernández, Víctor Rodríguez-Laval, Concepción Blanco, Betina Biagetti, Manel Puig-Domingo, Mónica Marazuela","doi":"10.1177/20420188261441382","DOIUrl":"10.1177/20420188261441382","url":null,"abstract":"<p><strong>Background: </strong>Growth hormone and insulin-like growth factor 1 (IGF-1) have recently been linked to temporal muscle thickness (TMT) in acromegaly; however, the relationship between treatment response and TMT remains unclear.</p><p><strong>Objectives: </strong>To evaluate whether TMT correlates with treatment response and may serve as a surrogate marker of disease control in patients with acromegaly.</p><p><strong>Design: </strong>Retrospective longitudinal two-center study.</p><p><strong>Methods: </strong>Patients with acromegaly and non-functioning pituitary adenomas (NFPA) were included. TMT was measured on magnetic resonance imaging scans obtained before treatment initiation and after a 3-year follow-up. Baseline TMT was compared between groups. In patients with acromegaly, TMT was correlated with IGF-1 levels at diagnosis and over time, as well as with treatment response. Mixed-effects regression models adjusted for covariates were used to assess associations.</p><p><strong>Results: </strong>Imaging studies from 58 subjects were analyzed (40 with acromegaly, 18 with NFPA). Pre-treatment TMT was significantly greater in patients with acromegaly compared with NFPA (mean 10.1 mm (9.3-10.7) vs 8.1 mm (8.0-9.2), <i>p</i> = 0.003). Higher baseline TMT was associated with higher IGF-1 levels at diagnosis (<i>p</i> < 0.01). Following treatment, mean TMT decreased from 9.6 mm at baseline to 8.8 mm at 36 months (<i>p</i> = 0.001). In covariate-adjusted mixed-effects models, higher pre-treatment TMT was independently associated with increased IGF-1 levels at diagnosis and longitudinally (β = 19.59 ng/mL, <i>p</i> = 0.022).</p><p><strong>Conclusion: </strong>TMT correlates with biochemical disease activity and decreases after treatment, suggesting it may be a useful imaging marker of clinical activity and prognosis in acromegaly.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261441382"},"PeriodicalIF":7.8,"publicationDate":"2026-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147820695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden variable in a \"neutral\" upgrade: why parameter re-tuning and perceived reliability matter after G6 → G7 in Control-IQ.","authors":"Xiaowei Zhang","doi":"10.1177/20420188261424319","DOIUrl":"10.1177/20420188261424319","url":null,"abstract":"","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261424319"},"PeriodicalIF":7.8,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13111884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study.","authors":"Hui-Hsia Hsieh, Wan-Yi Lee, Cheng-Li Lin, Chi-Hua Chen, Fuu-Jen Tsai, Bang-Jau You, Ni Tien, Yi-Jen Fang, Yun-Ping Lim","doi":"10.1177/20420188261442014","DOIUrl":"10.1177/20420188261442014","url":null,"abstract":"<p><strong>Background: </strong>The causes of cardiovascular disease are complex, with hyperlipidemia being a major factor in its development. The connection between peptic ulcer disease (PUD) and hyperlipidemia is unclear, and there have been no thorough studies on the effect of anti-PUD medications on the risk of hyperlipidemia, particularly in Asian populations. This study aimed to explore the relationship among PUD, anti-PUD medications, and the risk of developing hyperlipidemia.</p><p><strong>Objectives: </strong>Utilizing a population-based cohort study conducted in Taiwan, we investigated the association between PUD, the administration of anti-PUD medications, and the subsequent risk of developing hyperlipidemia.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Methods: </strong>Using data from the Taiwan National Health Insurance Research Database, we conducted a 21-year follow-up study on patients diagnosed with PUD between 2000 and 2021. The Cox proportional hazards regression model was used to analyze the risk of developing hyperlipidemia in relation to PUD and the use of anti-PUD medications.</p><p><strong>Results: </strong>According to the multivariable Cox proportional hazards regression analysis, patients with PUD had a higher overall incidence of hyperlipidemia (80.7 vs 53.6 per 1000 person-years) than those without PUD. The adjusted hazard ratio was 1.64 (95% confidence interval = 1.62-1.67). Both men and women, as well as different age groups, showed a higher risk of hyperlipidemia among patients with PUD. Patients with PUD who undergo surgery have a higher risk of developing hyperlipidemia than those who do not. The use of anti-PUD medications, such as H2 receptor antagonists, proton pump inhibitors, antibiotics, prostaglandin analogs, anticholinergics, antacids, and carbenoxolone, but not bismuth salts, was associated with a lower risk of developing hyperlipidemia than non-use.</p><p><strong>Conclusion: </strong>Patients with PUD were more likely to develop hyperlipidemia. However, patients receiving anti-PUD medications had a lower incidence of hyperlipidemia.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"17 ","pages":"20420188261442014"},"PeriodicalIF":7.8,"publicationDate":"2026-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}